SLN
Silence Therapeutics plc
$10.39
-0.11 (-1.05%)
At close · Jul 2
Market Cap
$1.47B
Shares
141,703,840
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.39
Open$10.66
Day$10.17–11.06
52W$4.19–11.06
Avg vol 30d425K
Short int2.1M · 1.5% float · 8.6d
Short vol13%
Last earningsMay 7, 2026
DataSep 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+65% above
+
Price vs 50-day avg
+42% above
−
RSI (14)
73 · overbought
+
MACD trend
positive
+
52-week position
90% · near high
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $7 › 200d $6 — 50d above 200d
−
Institutional flow
-3% holders QoQ · +6 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
1.46% of float · ▲ +0.4% MoM · 8.6 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
56 holders — mid 3-yr range
Fundamentals
Weak
−
Revenue growth
−99% Y/Y
+
Gross margin
62%, contracting
−
EPS growth
−91% Y/Y
−
Free cash flow
$-62.3M
+
Balance sheet
net cash $11.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+65% above
Bullish
Price vs 50-day avg
+42% above
Bullish
RSI (14)
73 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
90% · near high
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.46% of float · ▲ +0.4% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $10 · 90%
52-wk high $11
vs 200-day avg +65%
vs 50-day avg +42%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLN
this stock
Silence Therapeutics plc
|
$1.47B | +70.9% | +46.1% | — | 1.5% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLN | +3.9% | +62.1% | +79.1% | -5.4% | +70.9% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +2.5% | +63.3% | +71.1% | -5.1% | +61.7% |